Newswise — The Brexit vote has left U.K. scientists in an uncertain position, with no idea what the future research landscape may look like. Many fear it will slash funding. U.K. science has benefited financially from EU membership, winning more research grants than any country except Germany, while domestic science funding has lagged, according to several analysts. In addition, if the U.K. restricts the movement of people into the country, it may become more difficult for some EU students and postdocs to study and work there, hampering the sharing of research expertise. Scientists worry that international collaborations will become more cumbersome, impeding progress. The large multinational projects that are advancing dementia research throughout Europe may be hit particularly hard. Some fear the Brexit could encourage a brain drain from the U.K., as scientists seek more open environments to advance their research. Alzforum reports.
About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.
RSS